Monocytes as Predictors of Cystic Fibrosis-related Bone Disease (MucOs)

Study of Blood Monocytes as a Predictive Marker of Cystic Fibrosis-related Bone Disease

Hypothesis: Circulating monocytes RANK and MCSF-R expression is predictive of Cystic Fibrosis-related Bone Disease.

Study design: Single-center comparative cross-sectional study Population: Patients with a CFTR channel mutation causing cystic fibrosis consulting the Centre de Ressources et de Compétences de la Mucoviscidose (CRCM) at Reims University Hospital will be recruited. Healthy controls will be recruited from donors at the Etablissement Français du Sang Grand Est, Reims.

Judgment criteria:

- Main judgment criterion: X Expression level of CD115 (MCSF receptor) and CD265 (RANK) evaluated by flow cytometry receptors on the membranes of circulating monocytes.

- Secondary judgment criteria: X Rate of circulating CD115 +, CD265 +, CD115 + / CD265 + monocytes X Number of multinucleated cells with more than 2 nuclei and with an actin ring observed under fluorescence microscopy after osteoclastic differentiation X Surface of dentin resorbed in vitro by osteoclasts during an osteoclastic functionality test on dentin X Serum S1P levels assayed by ELISA technique.

Investigation plan:

Any eligible patient will be offered to participate in the study during the consultation at the CRCM. If the patient agrees to participate in the study, he/she will be included. Participation in the study will not affect its coverage. Participation will lead to the collection of three tubes of whole blood additional to those used as part of usual care, as well as the collection of demographic data (age, sex, height, weight, body mass index), sports practice, clinical images and interpretation, medical history (diabetes, infectious status, bone metabolism disorders, drug treatments followed, psychiatric disorders). Any subsequent donor from the EFS GE collected under the ALC / PIL / DIR / AJR / FO / 606 agreement and presenting characteristics of age +/- 2 years and identical gender will then be included.

Statistical analysis plan:

Qualitative variables will be described in terms of number and percentage. The quantitative distribution variables according to the Normal law will be described in the form of mean +/- standard deviation or in the form of boxplots (median, quartiles, deciles) if a distribution not following the Normal law is observed. ANOVA test, non-parametric Wilcoxon signed-rank test or chi² test will be aplied depending on the application conditions. A value of p <0.05 will be considered statistically significant.

Study Overview

• Status: Recruiting
• Conditions: Cystic Fibrosis
• Intervention / Treatment: Other: No intervention

• Study Type: Observational
• Enrollment (Anticipated): 80

Contacts and Locations

• Study Contact: Name: Bruno RAVONINJATOVO; Phone Number: 03 26 78 38 68; Email: bravoninjatovo@chu-reims.fr

Study Locations

• France
  • Reims, France
    • Recruiting
    • Université de Reims Champagne-Ardenne

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 20 years to 65 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Cystic fibrosis patients consulting the CRCM of Reims University Hospital. Healthy controls from Etablissement Français du Sang Grand Est, Reims

Description

Inclusion Criteria:

• Patients between 20 and 65 years (+/- 2 years)
• Patients of the CRCM of Reims University Hospital
• Patients with at least one CF causing mutation in CFTR gene
• Patients agreeing to participate in the study (informed consent form)
• Patients fluent in French
• Patients affiliated with a social security regimen
• Healthy donors between 20 and 65 years (+/- 2 years)
• Healthy donors giving blood at EFS GE, Reims
• Healthy donors agreeing to participate in the study (informed consent form)
• Healthy donors fluent in French
• Healthy donors affiliated with a social security regimen
• Healthy donors whose characteristics agree with the ALC/PIL/DIR/AJR /FO/606 convention between EFS GE, Reims, and Reims Champagne-Ardenne University

Exclusion Criteria:

• Patient having a medical history that may compromise the protocol (psychiatric, medical or pharmacological disorders such as the use of anti-inflammatory drugs, or any compound that may alter or modify the inflammatory reaction in the week preceding the protocol).
• Pregnant or breastfeeding women
• Patient with eating disorders (anorexia, bulimia, overeating)
• Patient protected by law (guardianship, curatorship, hospitalized without their consent and not protected by law, deprived of liberty)

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
CF; Patients with Cystic Fibrosis	Other: No intervention; No intervention

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of CD115 and CD265 expression on circulating monocytes	Flow cytometry	Immediately after sampling

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Assessment of CD115+, CD265+ and CD115+/CD265+ cells	Flow cytometry	Immediately after sampling
Count of multinucleated cells with actin ring	Phalloïdin/DAPI staining and microscope observation	3 weeks after sampling
Measurement of resorbed dentin surface	Scanning electron microscopy	3 weeks after sampling
Measurement of serum S1P concentration	ELISA	Immediately after sampling

Collaborators and Investigators

• Sponsor: Université de Reims Champagne-Ardenne
• Investigators: Principal Investigator: Bruno RAVONINJATOVO, Centre de Ressources et de Compétences de la mucoviscidose

Study record dates

Study Major Dates

• Study Start (ACTUAL): June 1, 2021
• Primary Completion (ANTICIPATED): November 1, 2025
• Study Completion (ANTICIPATED): November 1, 2025

Study Registration Dates

• First Submitted: April 27, 2021
• First Submitted That Met QC Criteria: May 3, 2021
• First Posted (ACTUAL): May 7, 2021

Study Record Updates

• Last Update Posted (ACTUAL): May 18, 2022
• Last Update Submitted That Met QC Criteria: May 17, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Keywords: Cystic Fibrosis; Monocytes; Bone disease; RANK; Osteoclast; MCSF-R
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Respiratory Tract Diseases; Lung Diseases; Infant, Newborn, Diseases; Genetic Diseases, Inborn; Musculoskeletal Diseases; Pancreatic Diseases; Fibrosis; Cystic Fibrosis; Bone Diseases
• Other Study ID Numbers: 2020-006-MucOs

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No